DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Zytiga (Abiraterone Acetate) - Summary



Abiraterone acetate, the active ingredient of ZYTIGA is the acetyl ester of abiraterone. Abiraterone is an inhibitor of CYP17 (17alpha±-hydroxylase/C17,20-lyase). Each ZYTIGA tablet contains 250 mg of abiraterone acetate.

ZYTIGA in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC) who have received prior chemotherapy containing docetaxel.

See all Zytiga indications & dosage >>


Published Studies Related to Zytiga (Abiraterone)

Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. [2013]
pain and functional status in a preplanned interim analysis of a phase 3 trial... INTERPRETATION: Abiraterone plus prednisone delays patient-reported pain

Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. [2012]
docetaxel chemotherapy... INTERPRETATION: In patients with metastatic castration-resistant prostate cancer

Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy. [2013]
validated fatigue-specific instrument... CONCLUSIONS: In patients with mCRPC progressing after docetaxel chemotherapy,

Abiraterone acetate: a novel drug for castration-resistant prostate carcinoma. [2012]
Androgen-deprivation therapy is the mainstay of treatment for the management of advanced prostate carcinoma till transition to castration-resistant prostate carcinoma (CRPC)... Searches of Pubmed, Cochrane database, Medscape, Google and clinicaltrial.org were made for terms like CRPC and abiraterone.

Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer. [2012]
to assess the effect of AA and abiraterone on the QT interval... CONCLUSIONS: There is no significant effect of AA plus prednisone on the QT/QTc

more studies >>

Clinical Trials Related to Zytiga (Abiraterone)

A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate [Recruiting]
A 2-part, Phase 1-2, open-label, parallel group, randomized study in patients with Castration-Resistant Prostate Cancer (CRPC) who are no longer responding to treatment with abiraterone and steroids. In Part A (Phase 1), patients will continue to receive the same doses of abiraterone and steroids they were receiving prior to study entry and will be randomized to receive 1 of 2 different treatment regimens of AT13387 in combination with abiraterone. Once the best regimen is established in Part A, based on safety and antitumor activity, patients will be randomized to the selected treatment regimen and dose of AT13387 in combination with abiraterone or AT13387 alone in Part B (Phase 2).

Pharmacodynamic Study of Abiraterone in the Treatment of Advanced Prostate Cancer [Not yet recruiting]
The purpose of this study is to evaluate the molecular effects of Abiraterone acetate and prednisone on prostate cancer. Participants will take Abiraterone acetate plus prednisone. While taking these drugs, patients will undergo sampling of cancer: one before treatment and one during treatment. To measure the body's overall response to Abiraterone acetate, the study follows patients for Prostate Specific Antigen (PSA) levels, cancer symptoms, and any side effects.

A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy [Recruiting]
The purpose of this study is to assess the safety and efficacy of oral abiraterone acetate plus oral prednisone and oral abiraterone acetate plus oral prednisone plus oral exemestane, each compared with oral exemestane alone, in postmenopausal women with estrogen receptor-positive (ER+) metastatic (spreading) breast cancer that has relapsed after treatment with letrozole or anastrozole.

A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer [Not yet recruiting]
There will be two parts to this clinical research study. The purpose of each part is:

- Phase 1: This part of the study will determine what dose of BEZ235 is safe to give with

a standard dose of abiraterone acetate and prednisone by administering different doses of BEZ235. This will help to find out what effects, good and/or bad, this combination has on CRPC.

- Phase 2: This part of the study will measure the treatment effect of the combination of

BEZ235 and abiraterone acetate/prednisone on CRPC.

Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer [Recruiting]
This phase II trial studies how well giving abiraterone acetate and prednisone with or without dasatinib works in treating patients with metastatic, hormone-resistant prostate cancer. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as abiraterone acetate, may lessen the amount of androgens made by the body. Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether abiraterone acetate and prednisone is more effective than abiraterone acetate, prednisone, and dasatinib in treating prostate cancer

more trials >>

Reports of Suspected Zytiga (Abiraterone) Side Effects

Prostatic Specific Antigen Increased (55)Death (42)Oedema Peripheral (35)Fatigue (32)Pain (26)Drug Ineffective (25)Confusional State (24)Weight Decreased (24)Blood Alkaline Phosphatase Increased (22)Thrombocytopenia (21)more >>

Page last updated: 2014-12-01

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015